4 hard stops: History of medullary thyroid cancer (yours or a close relative's), Multiple Endocrine Neoplasia type 2 (MEN2), a known allergic reaction to a GLP-1, or pregnancy. These are written into the label, non-negotiable.
6 serious cautions: Prior pancreatitis, gastroparesis or gut motility issues, severe kidney disease, active gallbladder disease, significant liver impairment, and diabetic retinopathy. Not automatic disqualifiers, but real conversations to have.
The bottom line: A good prescriber asking hard questions isn't a roadblock, it's the job. Know your history. Be honest with your doctor. The rest is their call to make with you.
GLP-1s have changed the conversation around weight and metabolic health. But they're not right for everyone, and a good prescriber is going to ask a lot of questions before writing that script. Understanding why matters, whether you're just starting the conversation or supporting someone who is.
There are two categories of reasons a doctor may not prescribe a GLP-1: hard stops, conditions that are written into the prescribing label as absolute contraindications, and clinical cautions, where the doctor weighs risk against benefit on a case-by-case basis. Knowing the difference helps you walk into that appointment prepared.
Hard Stops, The Absolute Contraindications
Medullary Thyroid Carcinoma (MTC), Personal or Family History
GLP-1 receptor agonists carry a black box warning for thyroid C-cell tumors. Animal studies showed that drugs like liraglutide triggered calcitonin release and C-cell hyperplasia in rodents. The effect in humans isn't fully established, but the prescribing information is unambiguous: if you or a close family member has a history of medullary thyroid cancer, GLP-1s are off the table.[1,2,3]
Multiple Endocrine Neoplasia Type 2 (MEN2)
MEN2 is a rare genetic condition that significantly raises the risk of medullary thyroid cancer. Because of that thyroid connection, GLP-1s are contraindicated in anyone diagnosed with MEN2A or MEN2B, same reasoning, same hard stop.[1,2]
Known Drug Allergy or Hypersensitivity
Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. If you've had a serious allergic reaction to one, prescribers will be cautious about all others in the class, the cross-sensitivity risk is not well characterized.[3]
Pregnancy
Animal studies have shown reproductive toxicity with all GLP-1 receptor agonists. GLP-1s are contraindicated during pregnancy and are not recommended during breastfeeding. Women of childbearing age are generally advised to use effective contraception while on these medications, and to stop at least two months before a planned pregnancy due to the long washout period.[1,2,3]
Clinical Cautions, "Let's Think About This Together"
These aren't automatic disqualifiers, but a careful prescriber will want to discuss them. The decision depends on how significant the condition is and how much benefit you're likely to gain.
Pancreatitis, History Of
GLP-1s have been associated with acute pancreatitis, and combining that risk with an existing history of the condition is a combination most prescribers avoid. If pancreatitis is suspected at any point during treatment, the medication should be discontinued.[1,3,4]
Gastroparesis or Gut Motility Disorders
One of the primary ways GLP-1s work is by slowing gastric emptying, your stomach holds food longer. That's useful for reducing appetite, but if you already have impaired gut motility (from diabetic gastroparesis, Parkinson's disease, or similar conditions), slowing it further can cause serious problems. Inflammatory bowel disease is also on this caution list.[1,4]
Severe Kidney Disease
Nausea and vomiting, common side effects, especially early on, can cause dehydration that accelerates kidney decline. Some GLP-1s (particularly older exenatide formulations) are primarily cleared through the kidneys. Most prescribers check an eGFR (kidney function number) before prescribing, and an eGFR below roughly 30 mL/min is often a stopping point.[2,4]
Gallbladder Disease
GLP-1s increase the risk of gallstones (cholelithiasis). In Ozempic clinical trials, gallstones were reported in roughly 1.5% of treated patients versus nearly zero in placebo. If you already have active gallbladder disease, that's a conversation worth having with your prescriber.[3]
Severe Liver Impairment
Most GLP-1s are broken down through general protein metabolism pathways rather than primarily through the liver, but safety and efficacy data in patients with significant liver disease is limited. Prescribers are generally advised to use caution in this population.[2]
Diabetic Retinopathy
A rapid drop in blood sugar, which GLP-1s can accelerate in people with diabetes, has been associated with temporary worsening of diabetic eye disease in some clinical trials. Patients with existing retinopathy should be monitored during treatment.[3]
A Note on Surgical Procedures
Because GLP-1s slow stomach emptying, residual food in the stomach during general anesthesia raises the risk of aspiration pneumonia. Major medical societies now recommend that anyone on a GLP-1 inform their entire care team, surgeon and anesthesiologist included, before any elective procedure. Most patients can continue their medication, but high-risk individuals may be advised to follow a liquid diet in the 24 hours before surgery.[5]
A Note from Cliff
When I started this journey, I had to answer a lot of those questions. Some felt scary to dig into. But the more I understood why those questions existed, the more confident I felt in the process, and in the people helping me. A good prescriber isn't putting up roadblocks. They're doing their job. And if something on this list applies to you, that's not the end of the road. It's just a more specific conversation to have. Always work with your doctor, that part's non-negotiable.
The Bottom Line
The hard stops, thyroid cancer history, MEN2, hypersensitivity, and pregnancy, are written into the FDA prescribing label and aren't negotiable. The cautions are where a skilled prescriber earns their keep: weighing what you stand to gain against the risks your specific history creates.
The rapid expansion of GLP-1 prescribing, including through telehealth platforms, has raised real concerns about patients not being properly screened for these conditions before starting treatment. Getting the right information to the right prescriber matters. That's exactly why education like this exists.
📋 Educational Content Disclaimer
This article is for educational and informational purposes only. It is not medical advice, does not constitute a diagnosis or treatment recommendation, and should not be used as a substitute for the guidance of a licensed healthcare provider.
GLP-1 receptor agonists are FDA-approved medications for specific indications. Individual eligibility, dosing, and risk assessment must be determined by a qualified prescriber based on your personal health history.
BritePear is a personal health transparency and education platform. Cliff's journey is shared to inform and encourage, not to recommend any specific treatment or protocol for others.
Sources & References
- Preuss CV, et al. "Glucagon-Like Peptide-1 Receptor Agonists." StatPearls [Internet]. Updated February 29, 2024. National Library of Medicine. ncbi.nlm.nih.gov/books/NBK551568
- Kalra S, et al. "Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force." Diabetes Therapy. PMC6778554. pmc.ncbi.nlm.nih.gov/articles/PMC6778554
- FDA Prescribing Information, Ozempic (semaglutide). accessdata.fda.gov. FDA Label PDF
- Osbourne-Roberts TK. "GLP-1 RAs: When Not to Prescribe." Medscape / MDEDGE. December 31, 2024. mdedge.com
- American Society of Anesthesiologists. "New Multi-Society GLP-1 Guidance." October 2024. asahq.org